GlobalData on MSN18d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Too Old to Operate11d
Low Vitamin D in Patients With Nasal Polyps: A Biomarker & Potential Treatment Target
Low vitamin D in patients with nasal polyps negatively correlated with several markers, including Lund-Mackay and total nasal ...
Yahoo Finance18d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...
Business Insider21d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
CRSwNP, for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is estimated that about 107 million people in China suffer from chronic sinusitis ...
Business Insider21d
GSK’s Nucala Gains Approval in China for CRSwNP
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic ...
AOL21d
GSK's Sinus Disease Drug Secures Approval In China
Also Read: GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market – Here's Why People with CRSwNP experience symptoms such as nasal obstruction, loss of smell ...
Investing21d
Optinose stock price target raised at H.C. Wainwright given reverse split
XHANCE is the first and only approved treatment for patients with chronic rhinosinusitis without nasal polyps (CRSsNP), as well as for those with nasal polyps (CRSwNP). The analysts' optimism is ...
pharmaphorum3d
FDA says no to AZ's Fasenra for nasal polyp indication
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
Hosted on MSN21d
GSK gets approval in China for Nucala for rhinosinusitis
GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal ...
FiercePharma1d
Regulatory tracker: Cancer drugs from J&J, GSK pick up new approvals in Europe
UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a ...
Too Old to Operate4d
Interviewing Patients on PROMs Improves CRSwNP Outcomes
A patient-reported outcome (PRO) measure consisting of verbal response scales to assess symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP) was well understood by patients and focused on the ...